Search

Your search keyword '"S. Morlino"' showing total 115 results

Search Constraints

Start Over You searched for: Author "S. Morlino" Remove constraint Author: "S. Morlino"
115 results on '"S. Morlino"'

Search Results

1. Anti-PSMA 124I-scFvD2B as a new immuno-PET tool for prostate cancer: preclinical proof of principle

2. A predictive model to personalize follow up schedules for patients in active surveillance

3. KS02.5.A COVID19 impact on the neuro-oncological population. evaluation of critical issues and resources of patients and caregivers

4. Development of a method for generating SNP interaction-aware polygenic risk scores for radiotherapy toxicity

6. PH-0119: Modulations of gut microbiota following radiotherapy for prostate cancer

7. A predictive model to personalize follow up schedules for patients in active surveillance

8. REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer

9. Hadrontherapy from the Italian Radiation Oncologist point of view: face the reality. The Italian Society of Oncological Radiotherapy (AIRO) survey

10. Phase II Multi-institutional Clinical Trial on a New Mixed Beam RT Scheme of IMRT on Pelvis Combined with a Carbon Ion Boost for High-risk Prostate Cancer Patients

11. Compliance of prostate cancer patients on active surveillance to protocol criteria: The experience of a large mono-institutional population

12. Evaluation of Mediators Associated with the Inflammatory Response in Prostate Cancer Patients Undergoing Radiotherapy

13. OC-0616 Introducing information on gut microbiota into toxicity modeling: preliminary results from a trial

14. Do number of biopsies and PSA doubling time at 3 and 5 years in active surveillance protocols associate with upgrading reclassification?

15. Radiotherapy for oligometastatic cancer: a survey among radiation oncologists of Lombardy (AIRO-Lombardy), Italy

16. Physicists' views on hadrontherapy: a survey of members of the Italian Association of Medical Physics (AIFM)

17. Clinical Results for an Active Surveillance Cohort with Localized Prostate Cancer Receiving RT after Exiting Active Surveillance

18. Evaluation of Inflammatory Marker Levels in Patients Treated with Radiation Therapy for Prostate Cancer

19. Active surveillance in prostate cancer patients: Predicting the chance of continuing AS after re-biopsy

20. Favourable and reliable PSA doubling time can improve confidence in reducing the number of repeat biopsy during active surveillance

21. Reclassification due to upgrading during active surveillance protocols in low risk prostatic cancer: The role of number of repeat biopsies in the long terms

22. Identification of a second HOXA2 nonsense mutation in a family with autosomal dominant non-syndromic microtia and distinctive ear morphology

23. Patient-reported intestinal toxicity from whole pelvis intensity-modulated radiotherapy: First quantification of bowel dose-volume effects

24. Follow-up of elderly patients with urogenital cancers: Evaluation of geriatric care needs and related actions

25. PO-0846: Bowel dose-volume relationship for patientreported acute intestinal toxicity from pelvic IMRT

26. Active surveillance in prostate cancer patients: Modeling upgrading and upsizing at 1 year rebiopsy

27. Effect of radiochemical modification on biodistribution of scFvD2B antibody fragment recognising prostate specific membrane antigen

28. A validation analysis confirming different predictors of upgrading and upsizing at 1-year repeat biopsy in low-risk prostate cancer patients on active surveillance

29. Breathing-Induced Prostate Motion: Real-Time Data Show Second-Order Effects

30. Weekly Integral Dose and Use of Lipid Lowering Drugs Are Associated With Worsening of Functional Outcomes in Prostate Cancer Patients Treated With IMRT

31. Analysis of electromagnetic transponders tracking data to quantify intrafraction prostate motion during radiotherapy treatments

32. Patient's breathing during prostate radiotherapy sessions: Is it really a second order effect?

33. Dosimetric impact of contouring variability for prostate cancer patients undergoing combined carbon ions/photons treatment (AIRC-IG 14300)

34. PO-0730: Urinary and erectile function in prostate cancer patients: radical radiotherapy vs active surveillance

35. 824 PRIAS vs SAINT: Comparing two active surveillance protocols

36. P065 Active Surveillance in prostate cancer: 8 years' experience

37. P063 Different predictors of upgrading and upsizing at 1-year repeat biopsy in men with low-risk prostate cancer undergoing active surveillance in prospective trials

38. Multidimensional geriatric evaluation at initial treatment in urological neoplasia: A cooperative prospective study

39. P095 Defining patient-specific rectal and bladder dose constraints for stereotactic body radiation therapy of the prostate: An evidence-based method

40. EP-0997 ADJUVANT HYPOFRACTIONATED RADIOTHERAPY AFTER CONSERVING SURGERY FOR EARLY BREAST CANCER IN ELDERLY WOMEN

41. 202: Mediators associated to the inflammatory response in prostate cancer patients undergoing RT: preliminary results

43. P064 Evaluation of mediators associated to the inflammatory response in prostate cancer patients undergoing radiotherapy: Preliminary results

45. PD-0498: Use of STAT in prostate cancer: correlation with risk factors and identification of residual cohort

46. P087 Use of a standardized total average toxicity score in a population of prostate cancer patients radically treated with radiotherapy: Correlation with clinical and dosimetric risk factors and determination of the exceptionally radio-sensitive cohort

47. PO-0672 QUALITY OF LIFE IN PROSTATE CANCER PATIENTS: RADIOTHERAPY COMPARED TO ACTIVE SURVEILLANCE

49. Improving plan quality and consistency by standardization of dose constraints in prostate cancer patients treated with cyberknife

50. EP-1374: Contouring guideline optimisation for prostate pts undergoing carbon ions/photons combined treatment

Catalog

Books, media, physical & digital resources